Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trialAndreas Glenthøj, Wilma Barcellini, Eduard J. van Beers et al.|The Lancet Haematology|2022Cited by 49
Effects of AG-348, a Pyruvate Kinase Activator, on Anemia and Hemolysis in Patients with Pyruvate Kinase Deficiency: Data from the DRIVE PK StudyRachael F. Grace, Bertil Glader, Christian Rosé et al.|Blood|2016Cited by 6
Early-Onset Osteopenia and Osteoporosis in Patients with Pyruvate Kinase DeficiencyHanny Al‐Samkari, Eduard J. van Beers, Rachael F. Grace et al.|Blood|2020Cited by 5
Early‐onset reduced bone mineral density in patients with pyruvate kinase deficiencyHanny Al‐Samkari, Eduard J. van Beers, Rachael F. Grace et al.|American Journal of Hematology|2023Cited by 4
Bone Mineral Density Remains Stable in Pyruvate Kinase Deficiency Patients Receiving Long-Term Treatment with MitapivatHanny Al‐Samkari, Eduard J. van Beers, Rachael F. Grace et al.|Blood|2021Cited by 3